StreetInsider.com News Articles

Goldman Sachs Drop Coverage of Fulcrum Therapeutics Inc. (FULC)

Tue, 02 Jun 2026 16:26:55 -0400

Goldman Sachs Drop Coverage of Fulcrum Therapeutics Inc. (NASDAQ: FULC).

The analyst comments "We have suspended our investment rating, price target, and earnings estimates for Fulcrum Therapeutics (FULC) because we have insufficient information on which to base an investment view. Our previous investment rating, price target, and earnings estimates are no longer in effect and should not be relied upon. We will continue to evaluate FULC's progress and ability to continue its business operations. On June 1, 2026, FULC reported the discontinuation of its clinical program evaluating pociredir in sickle cell disease following the receipt of FDA meeting minutes which reflect

JPMorgan Double Downgrades Fulcrum Therapeutics (FULC) to Underweight

Tue, 02 Jun 2026 16:26:10 -0400

JPMorgan downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Overweight to Underweight.

For an analyst ratings summary and ratings history on Fulcrum Therapeutics click here. For more ratings news on Fulcrum Therapeutics click here.

Shares of Fulcrum Therapeutics closed at $6.42 yesterday.

Fulcrum plummets over 50% after scrapping lead sickle-cell drug on FDA concerns

Tue, 02 Jun 2026 06:42:53 -0400

By Siddhi Mahatole

June 2 (Reuters) - Shares ‌of Fulcrum Therapeutics plunged 52% on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following cancer-risk concerns raised ‌by the U.S. FDA, and explore strategic options including a potential ⁠sale or merger.

The oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited

Fulcrum plummets over 50% after scrapping lead sickle-cell drug on FDA concerns

Tue, 02 Jun 2026 06:42:53 -0400

By Siddhi Mahatole

The oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited

Leerink Downgrades Fulcrum Therapeutics (FULC) to Market Perform

Tue, 02 Jun 2026 06:19:46 -0400

(Updated - June 2, 2026 6:19 AM EDT)

Leerink analyst Joseph P. Schwartz downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Outperform to Market Perform with a price target of $4.00.

The analyst comments "FULC announced the discontinuation of the pociredir program in sickle cell disease (SCD) following FDA feedback indicating that the agency does not believe the risk/benefit profile supports continued development. The decision is driven primarily by FDA's concerns surrounding the broader PRC2 (polycomb repressive complex 2) inhibitor class and the potential risk of secondary malignancies. We are surprised by this outcome given the magnitude and consistency of fetal hemoglobin (HbF) induction

Leerink Downgrades Fulcrum Therapeutics (FULC) to Market Perform

Tue, 02 Jun 2026 06:19:46 -0400

(Updated - June 2, 2026 6:19 AM EDT)

Leerink analyst Joseph P. Schwartz downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Outperform to Market Perform with a price target of $4.00.

H.C. Wainwright Downgrades Fulcrum Therapeutics (FULC) to Neutral

Tue, 02 Jun 2026 06:07:20 -0400

H.C. Wainwright analyst Andrew Fein downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Buy to Neutral with a price target of $3.00 (from $25.00).

The analyst comments "What’s new? Yesterday, Fulcrum announced the discontinuation of its pociredir program in sickle cell disease (SCD) following FDA feedback regarding the implications of secondary hematologic malignancies observed with Tazverik and its subsequent market withdrawal on the benefit-risk profile of pociredir in SCD. Fulcrum received meeting minutes from recent end-of-phase interactions with the FDA, which highlighted agency concerns regarding pociredir’s benefit-risk profile given the unexpectedly high rate of secondary hematologic malignancies observed with Tazverik, another PRC2 inhibitor

H.C. Wainwright Downgrades Fulcrum Therapeutics (FULC) to Neutral

Tue, 02 Jun 2026 06:07:20 -0400

H.C. Wainwright analyst Andrew Fein downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Buy to Neutral with a price target of $3.00 (from $25.00).

Piper Sandler Double Downgrades Fulcrum Therapeutics (FULC) to Underweight

Tue, 02 Jun 2026 01:08:50 -0400

Piper Sandler analyst Edward A. Tenthoff downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Overweight to Underweight with a price target of $3.00 (from $23.00).

The analyst comments: “Fulcrum is discontinuing the development of pociredir for the treatment of Sickle Cell disease (SCD). The decision follows FDA feedback highlighting concerns regarding the potential secondary hematologic malignancies associated with Polycomb Repressive Complex 2 (PCR2) inhibition. In March, the PCR2 inhibitor Tazverik was removed from the market due to the high risk of secondary blood cancers. Despite pociredir's different mechanism targeting the EED subunit vs EZH2 inhibitors like Tazverik, the FDA concluded that any pharmacologic

Piper Sandler Double Downgrades Fulcrum Therapeutics (FULC) to Underweight

Tue, 02 Jun 2026 01:08:50 -0400

Piper Sandler analyst Edward A. Tenthoff downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Overweight to Underweight with a price target of $3.00 (from $23.00).

Truist Securities Downgrades Fulcrum Therapeutics (FULC) to Hold

Tue, 02 Jun 2026 01:04:49 -0400

Truist Securities analyst Gregory Renza downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Buy to Hold with a price target of $4.00 (from $17.00).

The analyst comments: “After close today, FULC announced the unfortunate discontinuation of the development of pociredir following FDA concerns centered on malignancy risks associated with PRC2 complex inhibition. We had a chance to connect with mgmt, who reiterated the differences in EED subunit inhibition, and that of EZH2, the precedent for regulators in this decision, though ultimately, this was not sufficient to steer pociredir towards a more favorable outcome. At this time, FULC is undergoing a strategic review, and

Truist Securities Downgrades Fulcrum Therapeutics (FULC) to Hold

Tue, 02 Jun 2026 01:04:49 -0400

Truist Securities analyst Gregory Renza downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Buy to Hold with a price target of $4.00 (from $17.00).

Stifel Downgrades Fulcrum Therapeutics (FULC) to Hold

Mon, 01 Jun 2026 18:37:39 -0400

Stifel analyst James Condulis downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Buy to Hold with a price target of $3.00 (from $25.00).

The analyst commented, "FULC announced surprisingly that they're discontinuing development of pociredir following receipt of their post-ph1b FDA meeting minutes. Specifically, management noted the decision follows feedback regarding the implications of the secondary malignancies observed with tazemetostat (another PRC2i) that left no viable regulatory path forward. While safety has always been an overhang and we had noted the tazemetostat withdrawal (LINK), we were optimistic that there were nuances (dosing, subunit target--EED vs. EZH2, patient population/background risk, efficacy, etc.) that made

Stifel Downgrades Fulcrum Therapeutics (FULC) to Hold

Mon, 01 Jun 2026 18:37:39 -0400

Stifel analyst James Condulis downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Buy to Hold with a price target of $3.00 (from $25.00).

After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP

Mon, 01 Jun 2026 16:37:47 -0400

After-Hours Stock Movers

Hewlett Packard Enterprise (NYSE: HPE)

Hewlett Packard Enterprise skyrocketed 35% after hours, building on a 9% intraday gain, after posting a massive Q2 beat with an EPS of $0.79 and revenue of $10.7 billion. The stock's surge was further fueled by significantly raised Q3 and full-year fiscal 2026 guidance, easily clearing Wall Street expectations across the board.